BPC-157 TB-500 is a two-peptide research blend paired for complementary tissue-repair mechanisms.

Two peptides, sketched onto one page

BPC-157 TB-500 is a research-community pairing of two distinct synthetic peptides, marketed and discussed under the nickname "Wolverine." It is not a single chemical entity. It has no single molecular weight, no shared CAS number, and no approved therapeutic indication anywhere. What it has are two well-defined components and a hypothesis about why they belong together.

The first component is BPC-157 — Body Protection Compound 157 — a 15-amino-acid pentadecapeptide (sequence GEPPPGKPADDAGLV, ~1419.5 Da) derived from a protein found in human gastric juice. In preclinical models it acts as a local cytoprotective and pro-angiogenic signal, up-regulating VEGFR2 with downstream Akt-eNOS activation ^[2]. The second is TB-500, a synthetic N-acetylated heptapeptide (Ac-LKKTETQ, ~889 Da) corresponding to residues 17-23 — the actin-binding motif — of the 43-residue protein Thymosin Beta-4. Its helix binds monomeric G-actin in a 1:1 complex, regulating the cytoskeletal dynamics that drive cell migration ^[3].

The rationale for pairing them is mechanistic complement: a vascular-and-cytoprotection signal beside a cell-migration signal, converging on a tissue-repair node. That rationale is the drawn hypothesis on the page. The experiment that would test it has never been run. This site treats the components honestly — citing every quantitative claim to its source study — and keeps the combination's missing evidence visible rather than filled in. For the pharmacokinetic picture, see BPC-157 TB-500 dosage and pharmacokinetics; for the mechanisms, see BPC-157 and TB-500 mechanisms.

What Is the Wolverine peptide blend?

The Wolverine peptide blend is a research-community name for a two-peptide pairing of BPC-157 and TB-500, sold and discussed as a tissue-repair "stack." The name is branding, not chemistry. There is no "Wolverine molecule" — there are two peptides in one vial, often labeled with a combined per-vial mass such as 10 mg BPC-157 plus 10 mg TB-500.

The term carries a search problem worth naming: most online volume for "wolverine peptide" is conflated with the fictional character, not the compound. The clean compound-intent term is the pairing itself, BPC-157 TB-500.

What is the Wolverine peptide blend?

Wolverine is a research-community name for a two-peptide pairing of BPC-157 and TB-500, marketed and discussed as a tissue-repair "stack." It is not a single chemical entity, has no single molecular weight or CAS number, and is not an approved product anywhere. The components are two separate synthetic peptides combined in one vial.

The Wolverine stack: BPC-157 and TB-500 combined

The BPC-157 TB-500 stack pairs two peptides chosen for non-overlapping mechanisms. BPC-157 supplies the local angiogenic and cytoprotective leg — in transected rat Achilles tendon it improved load-to-failure, collagen organization, and tendon integrity versus untreated controls, and in vitro it reversed growth inhibition of tendocytes into stimulation ^[1]. TB-500 supplies the cytoskeletal leg, through the 1:1 G-actin sequestration its parent protein Thymosin Beta-4 was crystallographically shown to perform ^[3].

The word "stack" implies the combination has been worked out. It has not. A 2025 systematic review of BPC-157 in orthopaedic sports medicine examined 36 studies — 35 preclinical, only one human — found no clinical safety data, and made no mention of TB-500 or any combination ^[9]. The stack is two separately characterized peptides; the assembled product has never been tested as a unit. See why researchers pair the two peptides for the full mechanistic rationale.

What is BPC-157 and TB-500?

BPC-157 is a synthetic 15-amino-acid pentadecapeptide (sequence GEPPPGKPADDAGLV) derived from a human gastric-juice protein; TB-500 is a synthetic N-acetylated heptapeptide (Ac-LKKTETQ) corresponding to the actin-binding region of Thymosin Beta-4. The Wolverine blend pairs the two as a research-community tissue-repair stack; it is not a single chemical entity or an approved product.

What is the BPC-157 and TB-500 blend used for in research?

Its two components occupy complementary nodes of a tissue-repair network in preclinical work: BPC-157 for cytoprotection, angiogenesis, and tendon repair in rodent models ^[1], and TB-500 / Thymosin Beta-4 for actin-regulated cell migration and re-epithelialization in animal and biochemical models ^[4]. The assembled blend itself has not been tested in a controlled study.

What this notebook is — and is not

These pages keep a bench log of the published research on the BPC-157 TB-500 blend and its two components — a working record kept beside the studies, not a clinic, a pharmacy, or a place that sells anything."Chemical" in the name reads as the lab-bench register — a working notebook — not a storefront.

We state findings as they appear in the literature: a dose studied in a species by a route, an effect measured against a control, a mechanism resolved by a structure. Where the evidence is preclinical, we say so. Where it is single-compound rather than combination, we say so. And where it is absent — as it is for the blend's human efficacy and combination safety — we leave the entry blank rather than fill it in. The regulatory picture, including the FDA's current 503A category for both components, lives on Wolverine legal status and FDA 503A category.

New margin notes: reported effects and safety limits

The rev3 corpus adds a BPC-157 TB-500 effects and safety page to the notebook. Reported upsides and adverse effects remain labeled as anecdotes; the next section traces the blend's safety limits to audited sources and marks theoretical cautions as theoretical.